Administration of Four Different Doses of Gabapentin Reduces Awakening from Breakthrough Pain and Adverse Effects in Outpatients with Neuropathic Pain During the Initial Titration

Overview

Journal Korean J Anesthesiol

Specialty Anesthesiology

Date 2013 Aug 2

PMID 23904939

Citations 7

Authors

Jong-Yeun Yang

Won Il Lee

Woo-Kyung Shin

Cheul Hong Kim

Seong-Wan Baik

Kyung-Hoon Kim

Affiliations

Soon will be listed here.

Abstract

Background: Gabapentin is a safe and well-tolerated anticonvulsant with a wide therapeutic index, and it is used for neuropathic pain. The aim of this study was to compare previous dosing methods with the administration of four different doses of gabapentin while maintaining the same maximum daily dose for the safe administration of high doses of the medication.

Methods: THE SUBJECTS WERE OUTPATIENTS WITH VARIOUS NEUROPATHIC PAIN SYNDROMES, WITH AT LEAST TWO OF THE FOLLOWING SYMPTOMS: allodynia, burning pain, shooting pain, or hyperalgesia. The TID group received equal doses of gabapentin 3 times per day, while the QID group received 4 different doses of gabapentin per day. The pain score, frequency of breakthrough pain (BTP), severity and the duration of pain, sleep disturbance due to nocturnal pain, and adverse effects were recorded each day.

Results: The average daily pain score and sleep disturbance were significantly reduced in the QID group between days 3 and 10 of the experiment. The adverse effects of the medication were also reduced in the QID group. However, the frequency of BTP and severity and duration of pain were not significantly different between two groups.

Conclusions: Administration of 4 different doses of gabapentin during the initial titration in outpatients with neuropathic pain resulted in a significant reduction in awakening from breakthrough pain and a reduction in the adverse effects of the medication.

Citing Articles

Efficacy of gabapentin and pregabalin for treatment of post refractive surgery pain: a systematic review and meta-analysis.

Chen K, Chan H, Wei L, Chan C Int Ophthalmol. 2024; 44(1):409.

PMID: 39448432 DOI: 10.1007/s10792-024-03300-9.

Evaluation of Gabapentin as a Treatment of Breakthrough Cancer Pain Caused by Metastatic Prostate Adenocarcinoma.

Ismy J, Emril D, Khalilullah S, Mauny M J Pain Res. 2023; 16:3319-3324.

PMID: 37808465 PMC: 10558050. DOI: 10.2147/JPR.S422769.

Acute post-injury blockade of α2δ-1 calcium channel subunits prevents pathological autonomic plasticity after spinal cord injury.

Brennan F, Noble B, Wang Y, Guan Z, Davis H, Mo X Cell Rep. 2021; 34(4):108667.

PMID: 33503436 PMC: 8817229. DOI: 10.1016/j.celrep.2020.108667.

Beyond Amitriptyline: A Pediatric and Adolescent Oriented Narrative Review of the Analgesic Properties of Psychotropic Medications for the Treatment of Complex Pain and Headache Disorders.

Windsor R, Sierra M, Zappitelli M, McDaniel M Children (Basel). 2020; 7(12).

PMID: 33276542 PMC: 7761583. DOI: 10.3390/children7120268.

All about pain pharmacology: what pain physicians should know.

Kim K, Seo H, Abdi S, Huh B Korean J Pain. 2020; 33(2):108-120.

PMID: 32235011 PMC: 7136290. DOI: 10.3344/kjp.2020.33.2.108.

References

Morrell M, McLean M, Willmore L, Privitera M, Faught R, Holmes G . Efficacy of gabapentin as adjunctive therapy in a large, multicenter study. The Steps Study Group. Seizure. 2000; 9(4):241-8. DOI: 10.1053/seiz.2000.0407. View

Woolf C . Dissecting out mechanisms responsible for peripheral neuropathic pain: implications for diagnosis and therapy. Life Sci. 2004; 74(21):2605-10. DOI: 10.1016/j.lfs.2004.01.003. View

ROWBOTHAM M, Harden N, Stacey B, Bernstein P . Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. JAMA. 1998; 280(21):1837-42. DOI: 10.1001/jama.280.21.1837. View

Gidal B, DeCerce J, Bockbrader H, Gonzalez J, Kruger S, Pitterle M . Gabapentin bioavailability: effect of dose and frequency of administration in adult patients with epilepsy. Epilepsy Res. 1998; 31(2):91-9. DOI: 10.1016/s0920-1211(98)00020-5. View

Backonja M, Glanzman R . Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. Clin Ther. 2003; 25(1):81-104. DOI: 10.1016/s0149-2918(03)90011-7. View

Jean W, Wu C, Mok M, Sun W . Starting dose of gabapentin for patients with post-herpetic neuralgia--a dose-response study. Acta Anaesthesiol Taiwan. 2005; 43(2):73-7. View

Elwes R, Binnie C . Clinical pharmacokinetics of newer antiepileptic drugs. Lamotrigine, vigabatrin, gabapentin and oxcarbazepine. Clin Pharmacokinet. 1996; 30(6):403-15. DOI: 10.2165/00003088-199630060-00001. View

Norton J . Gabapentin withdrawal syndrome. Clin Neuropharmacol. 2001; 24(4):245-6. DOI: 10.1097/00002826-200107000-00011. View

Wilton L, Shakir S . A postmarketing surveillance study of gabapentin as add-on therapy for 3,100 patients in England. Epilepsia. 2002; 43(9):983-92. DOI: 10.1046/j.1528-1157.2002.01702.x. View

10.

Serpell M . Gabapentin in neuropathic pain syndromes: a randomised, double-blind, placebo-controlled trial. Pain. 2002; 99(3):557-566. DOI: 10.1016/S0304-3959(02)00255-5. View

11.

Payne R . Recognition and diagnosis of breakthrough pain. Pain Med. 2007; 8 Suppl 1:S3-7. DOI: 10.1111/j.1526-4637.2006.00269.x. View

12.

Gidal B, Radulovic L, Kruger S, Rutecki P, Pitterle M, Bockbrader H . Inter- and intra-subject variability in gabapentin absorption and absolute bioavailability. Epilepsy Res. 2000; 40(2-3):123-7. DOI: 10.1016/s0920-1211(00)00117-0. View

13.

Rice A, Maton S . Gabapentin in postherpetic neuralgia: a randomised, double blind, placebo controlled study. Pain. 2001; 94(2):215-224. DOI: 10.1016/S0304-3959(01)00407-9. View